Galderma Acne Ingredient Switch Receives NDAC Review In April
This article was originally published in The Tan Sheet
FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
You may also be interested in...
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.